BowTied Bull
111K+ subscribers
No non-sense writing style covering: 1) Crypto, 2) Tech Stocks, 3) WiFi money and 4) Real Estate. Written by anon Ex-Wall St and Tech Individuals. SPONSOR FREE.
Category
Money & Markets
Markets, macro, personal finance and biotech investing from the BowTied jungle. 6 publications, newest posts first.
Publications
BowTiedBroke
13K+ subscribers
Sharing my successes and failures in various finance, real estate and corporate life. What I did right (and wrong) in those various areas and what I learned in…
BowTiedBiotech
3K+ subscribers
Daily Biotech Public & Private Market Updates, Company Building, Financing, Exit Strategies, and Emerging Science Trends
Fs I Give
2K+ subscribers
Financial Advice with some rants on Fitness, Family, and general Fixing of Bad Advice You will learn what to do to get in the top 10% of health and wealth
Macro, Models, and Mutiny
Hundreds of subscribers
Models but also whatever I want
Notes from Underwater
Hundreds of subscribers
Psychology, Persuasion, and Markets.
Latest in Money & Markets
BowTiedBiotech Weekly: Big Pharma Wins and Biotech Markets | Ep. 1115
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Free
Read
Your Weekly Biotech News Fix | Ep. 1114
Hello Avatar! Another week of biotech news is in the history books. We are proud to bring you the latest edition of our weekly biotech news fix. The content is designed to be consumed as a quick scroll to bring readers up to…
Free
Read
Every $1,000 You Spend Is 5 Years Longer You Work - Part 1
Welcome back & Happy Halloween to those who celebrate (Apparently in 2026 you need that qualifier on Halloween now too or something). The F’er family does indeed go out for Halloween and despite my continued prodding the lil…
Paid
Read
Short Post on Binance Hack + Tech Earnings
Welcome Avatar! In a rare case we’ll go ahead and chime in on this recent event. Like any of these big scary headlines it usually ends up being (relatively) predictable. In addition to that, we did get some quick earnings after…
Paid
Read
The Last Drug You Have to Develop From Scratch | Ep. 1113
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary, as always on Thursday, focuses on the general market update. This week confirmed the playbook. Biotech can rally and capital can return quickly, but…
Free
Read
Three of Meta’s Muses and Why You Should Care for Small Biz Profits ($$$)
Welcome Avatar! Your favorite sewer-dwelling rodent returns ( CryptoMouse ), this time to talk the META Muse rule of three, Zuck AI edition. Caveat: Muse is a Meta brand, that covers both products and the AI models that power…
Paid
Read
Anthropic S-1 Highlights and Microsoft Cuts. Making Sense of the Madness
Welcome Avatar! Another day has gone by and the world has not ended. If you have looked at social media, the recent doom loop has suggested both the UK and Japan should prepare for days/weeks/months of mass cyber disruption.…
Free
Read
BIOTECH MARKET RESEARCH $SMMT | Ep. 1112
Summit Therapeutics ($SMMT) is a catalyst-driven setup centered on the November 14, 2026 FDA PDUFA for ivonescimab plus platinum-doublet chemotherapy in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer…
Paid
Read
Cost Cutting, AI Slowdown and Big Tech Fear Mongering. What is Real & What Isn’t
Welcome Avatar! Pretty wild weekend. We’ve got Elon calling for a slow down in the AI infrastructure build out. Big fears all over the timeline related to an energy related hack. And. A wave of layoffs at various large cap…
Paid
Read
The Business of Gene Editing | Ep. 1111
Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we’re diving into the…
Free
Read
BowTiedBiotech Weekly: Innovation, Safety, and Capital | Ep. 1110
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Free
Read
Direct Indexing - A Better ETF?
Welcome back. The end of the year is coming in hot. You know how it goes, Halloween → Thanksgiving → Christmas → New Years. And we also have the added benefit of nearly every member in the extended family having a Q4 birthday.…
Paid
Read
Real Yields and TIPS Markets
It is a common line of reasoning to cite the real yield-inflation breakeven decomposition and conclude that the move in bonds in the U.S. lately is showing rising growth expectations and not pricing any inflation. Read more
Paid
Read
Your Weekly Biotech News Fix | Ep. 1109
Hello Avatar! Another week of biotech news is in the history books. We are proud to bring you the latest edition of our weekly biotech news fix. The content is designed to be consumed as a quick scroll to bring readers up to…
Free
Read
Clearing Out Bloat to Adjust Earnings. And. Security Concerns
Welcome Avatar! As a quick preview for part of Sunday’s post, one thing we’re noticing is that old P/E and ETF analysis is no longer relevant in 2026. We’ve all watched as the same charts pop up. “20 companies are driving all the…
Free
Read
Weekly Expectations Summary (stocks, bonds, oil)
Check out the group chat for more detail here. Link below. Read more
Paid
Read
The End of the Impossible Trial | Ep. 1108
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary, as always on Thursday, focuses on the general market update. This week confirmed the playbook. Biotech can rally and capital can return quickly, but…
Free
Read
Is Your Company On the Right Side of the K and AI?
Welcome Avatar! Considering all the tech news we thought it would be a good time to quantify how some of our mega themes are playing out. The mega themes are still the same: 1) degeneracy, 2) loneliness, 3) K-shape Economy - rich…
Paid
Read
The Biotech Valuation Paradox | Ep. 1107
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Free
Read
BIOTECH MARKET RESEARCH $SYRE | Ep. 1106
Spyre Therapeutics ($SYRE) is a catalyst-driven setup centered on the expected Q4 2026 Phase 2 SKYWAY readouts for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). This is a clinical data catalyst testing…
Free
Read
Entrepreneurs Invest Too Much and Why You Will Too
Welcome Avatar! Several Jungle natives have created 7-8 figure brands at this point. With that in mind we think it’s a good time to give you a clean explainer for why Entrepreneurs end up over investing. This is the inverted…
Free
Read
Update on Trump, Russia, Ukraine March 24 Incredible Prediction (Stocks, Bonds, Oil)
I find myself frequently sharing this incredible prediction from March 24 (paywall has been removed on the paid article) lately so I thought it would be a good time to revisit the dynamic. Obviously much has happened since March…
Paid
Read
A Reminder That Crypto Has No Correlation. And. AI Slowdown with Likely Chain of Events
Welcome Avatar! It looks like we’re getting the hiccup for AI companies. In the end, we all know they will print money or drop interest rates to near zero. No other way around it. In the interim, good time to look at what is most…
Paid
Read
You Stand Up for Yourself
(I have multiple completed drafts from many months ago when this newsletter was figuring out its niche. My most recent article on austerity and inflation is unusually long so I’m taking the opportunity this week to share this…
Free
Read
China’s Quiet Clinical Revolution | Ep. 1105
Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we’re diving into the…
Free
Read
Back To Mortgages Part 2
Welcome back. Last week we went through all the silly arguments being made for why paying off a historically cheap mortgage is ‘better’ than keeping the mortgage plus buying significantly higher yielding US Treasury. Here is the…
Paid
Read
The Biotech Capital Comeback: AI, Clinical Breakthroughs, and the New Rules of Drug Development | Ep. 1104
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Free
Read
Q4 Sell-Off Shopping List - Quick Update
Welcome Avatar! Well it is officially October 16 so its time to actually care about crypto and high-tech. We’re seeing higher oil prices, bad inflation prints, likely some layoffs in the near-term and back to the money printer…
Paid
Read
Inflation Came in Hot, AI Growth Cooling - What to Do
Welcome Avatar! Pretty wild week and it looks like the Q4 pull down may happen we’re going to do a mini overview, reiterate our own strategy and write out where we think the opportunity is. In addition, since we’ll have purchases…
Paid
Read
The IRS Just Let You Fork Your Crypto Books
Welcome Avatar! This is a bonus guest post (standard paid post on Wednesday Night still coming) since we know we’re at tax deadline. For those that need an update we have a CPA here who does nothing buy crypto taxes. Best to get…
Free
Read
Using AI Will Make the K-Shape Worse
Welcome Avatar! If you’re a good operator, you’re not worried about AI. That has remained true the entire year. In fact, entry level people abusing AI are only making their lives worse. If the higher up recognizes that the…
Free
Read
Solving the Debt: Austerity or Inflation? (stocks, bonds, gold)
The origin of this article is a subscriber question about a throwaway Trump comment about paying off the debt recently (October 2). It’s a good question. People generally say what they mean; what they are actually thinking. 1 Not…
Paid
Read
Back To Mortgages
Thanks to BowTiedBull, my twitter feed is about 50% tweets about mortgage payoff - the other 50% is a mix of social security arguing and the standard nonsense that you have no idea why its popping up. If you have been a reader…
Paid
Read
Revisiting Trump and Putin’s Friendship
Trump has revoked more energy sanctions on Russia with the excuse of the ongoing diesel crisis. “Never let a crisis go to waste,” as they say. This is something I mentioned in March: how the geopolitical progressions would likely…
Paid
Read
Diversification
“Two is one, and one is none” This is the common saying used by faux Boomer prep-ers when they justify all the stuff they own. If you have ever been doing some handy work and realize you are missing some niche and expensive tool…
Paid
Read
October 2026 Asset Summary
I’m going to start doing a monthly asset summary (thanks to for the excellent suggestion). This will be nice because: My articles are generally concept-focused and finding my overall market views by reading through all my notes…
Paid
Read
Kpler’s Numbers are Right (Oil, Bonds, Stocks)
There aren’t major investment implications from this update but I’ve gotten asked about this by paid subs and it appears other friends of Notes From Underwater are boosting the claim so I thought it would be worth sending a short…
Paid
Read
5% to 1% to 0.1%: What It Really Takes
The Bell Curve. A lot of you may only be familiar with the bell curve from the memes. However, it is a concept that springs up again and again in the actual world. There are millions of these memes out there for every topic…
Paid
Read
Hacks, Crypto, and Bad Maf
Welcome back. This week we are combining a reader request for some thoughts about crypto with a vaguely crypto adjacent topic of hacks/scams and accounts being drained. The example of the hack in this post is a new one that I…
Paid
Read
Not Smarter. Not Harder.
Welcome Back Dear Reader. Do you consider yourself smart? Do you feel like you work hard? Yet, do you still feel like you are being left behind? Would you spend $204 for a $1 bill? You are not alone. In fact, a lot of smart and…
Paid
Read
“The Wealthy don’t buy Life Insurance”
Welcome back. Let’s start this week’s post with some good news. The Michael Dell philanthropy money for the Trump Accounts hit the lil F’ers accounts a few days ago. As discussed in the post about Trump accounts, there was some…
Paid
Read
2026Q3 Random Topics & $1,000 Free Money
Welcome back. Another week in the rearview and we are rolling into the last month of Q3. Every quarter there is a handful of topics that would be a stretch to make their own post, but fit perfectly as smaller, condensed sections.…
Paid
Read
Myths About Wealth & The Wealthy
Welcome Back. This week’s post is brought to you by one of the misguided budgetpoor accounts on twitter and a rehash (and probably scheduled to go off once every month) tweet: There are just so many directions you can go on…
Paid
Read
Cabin Fever - Part 2
Around 2008, when I was in the pest control business, the company I worked for serviced a large hotel chain. When we did pest control work for a large commercial brand, we would call those “National Accounts”. They were IMPORTANT…
Paid
Read